in this issue
Pharma/fine chemicals roundup—6 August 2013
5:02 AM MDT | August 6, 2013 | By DEEPTI RAMESH
Teva’s API business reports fall in sales
The active pharmaceutical ingredient (API) business of Teva Pharmaceutical Industries (Petaḥ Tiqwa, Israel) reports a 9.5% fall in sales in the second quarter of 2013, compared with the year-ago period, to $181 million. For the six-month period ended 30 June, the API business reports an 8% fall in sales, compared with the first six months of 2012, to $367 million. Teva has the largest API business in the world in terms of sales.
API business of Dr. Reddy’s reports rise in sales
The pharmaceutical services and active ingredients (PSAI) business of Dr. Reddy’s Laboratories (Hyderabad, India) reports a 6.1% rise in sales in the company’s fiscal first quarter, ended 30 June, compared with the year-ago quarter, to 5.86 billion Indian rupees ($96 million). Earnings figures for the PSAI business have not been disclosed. Growth in the business was muted because of fewer launch molecules to customers during the quarter, Dr. Reddy’s says. Europe accounted for about 36% of the company's PSAI sales in the quarter. North America accounted for 19%, India accounted for 13%, and the rest of the world accounted for 32%, Dr. Reddy’s says. Dr. Reddy’s has the second-largest active pharmaceutical ingredient business in the world in terms of sales, after Teva Pharmaceutical Industries (Petaḥ Tiqwa, Israel).
Saltigo moves headquarters to Leverkusen; to invest €100 million in active ingredients business
Saltigo (Langenfeld, Germany), a wholly owned subsidiary of Lanxess, is relocating its corporate headquarters from Langenfeld to Leverkusen, Lanxess says. In September, over 100 employees of Saltigo will move into what used to be Lanxess’s headquarters. Saltigo focuses on custom synthesis and manufacturing services for small molecules, and serves customers in the pharmaceutical, agrochemical, and specialty chemical industries. Saltigo operates production facilities at Leverkusen and Dormagen in Germany. In the future, about 1,100 of Saltigo’s 1,200 staff worldwide will work at the new headquarters at Leverkusen. Saltigo is also planning to invest up to €100 million ($131 million) in the agricultural active ingredients business at Leverkusen through 2015, Lanxess says.
Cambrex reports huge fall in profits
Cambrex (East Rutherford, NJ) reports a 77% fall in net profits for the second quarter, ended 30 June, compared with the year-ago quarter, to $2.27 million. Net sales for the second quarter decreased 19.3%, to $61.5 million, primarily because of lower sales of controlled substances and generic active pharmaceutical ingredients, Cambrex says. For the first six months of 2013, Cambrex reports a 20.7% fall in profits, compared with the first six months of 2012, to $13.4 million. Net sales in the first-half decreased by 7.1%, to $135.9 million.
Vivus signs API manufacturing deal with Sanofi
Biopharmaceutical company Vivus (Mountain View, CA) says that it has entered into a commercial supply agreement with Sanofi Chimie, a wholly owned subsidiary of pharmaceutical major Sanofi (Paris), to manufacture and supply the active pharmaceutical ingredient (API) for avanafil on an exclusive basis in the United States and other territories and on a semi-exclusive basis in the European Union and Latin America. Avanafil is drug for the treatment of erectile dysfunction. “Sanofi was the logical choice for avanafil API manufacturing,” says Theodore Broman, v.p./chemistry manufacturing and control at Vivus. “Their world-class manufacturing capabilities and facilities are well-suited to undertake the worldwide production of avanafil.” The qualification of Sanofi as a supplier of avanafil API, and as a bulk tablet manufacturer for avanafil, and the subsequent approval by regulatory authorities is expected to be completed by June 2015. Until such approvals, Vivus will continue to source avanafil API from Mitsubishi Tanabe Pharma.
Aesica appoints COO
Aesica Pharmaceuticals (Newcastle, UK) says it has appointed Chris Gowland to the newly created position of chief operating officer (COO). He will be responsible for the setting of operational standards and driving continuous improvement across the company’s manufacturing capabilities in active pharmaceutical ingredients (API) and formulated products. Gowland is now responsible for the general management of all Aesica manufacturing sites including Queenborough and Cramlington in the United Kingdom; Monheim and Zwickau in Germany; and Pianezza in Italy. Steve Barker and Jarrett Palmer, operations directors for the API and formulated products business units respectively, will report to the COO.
Bayer enters into cancer immunotherapy collaboration with Compugen
Bayer says that its Bayer HealthCare subgroup has entered into an oncology collaboration and license agreement with drug discovery company Compugen (Tel Aviv, Israel). The partnership will focus on the research, development, and commercialization of antibody-based therapeutics for cancer immunotherapy against two novel immune checkpoint regulators discovered by Compugen. Bayer and Compugen, under the agreement, will jointly pursue a preclinical research program; Bayer will have full control over further development and worldwide commercialization rights for potential cancer therapeutics.
IMCD acquires Capitol Ingredients in Australia and New Zealand
IMCD Group (Rotterdam) says that it has completed the acquisition of Capitol Ingredients Australia (Sydney), a specialty ingredients distributor focused on the nutraceuticals, personal-care, food and pharmaceutical markets in Australia and New Zealand.
Beyond IHS Chemical Week:
API, generic drug facilities hit with US FDA fee hikes for 2014
US and foreign generic drug manufacturers will see a more than $40,000 increase in US FDA facility fees for 2014, while API manufacturers will see a more than $8,000 increase.